Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis

被引：0
|
作者：
Shijie Lu
Yake Lou
Yi Rong
Zirui Huang
Xiaodan Lin
Junying Chen
Kongjia Luo
机构：
[1] Sun Yat-Sen University Cancer Center,State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
[2] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
来源：
Clinical Drug Investigation | 2023年 / 43卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：643 / 652
页数：9
相关论文
共 50 条
  • [1] Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
    Lu, Shijie
    Lou, Yake
    Rong, Yi
    Huang, Zirui
    Lin, Xiaodan
    Chen, Junying
    Luo, Kongjia
    CLINICAL DRUG INVESTIGATION, 2023, 43 (08) : 643 - 652
  • [2] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [3] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China
    He, Chaoneng
    Mi, Xiufang
    Xu, Gaoqi
    Xu, Xinglu
    Xin, Wenxiu
    Zhong, Like
    Zhu, Junfeng
    Shu, Qi
    Fang, Luo
    Ding, Haiying
    PLOS ONE, 2024, 19 (05):
  • [5] Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
    Lin, Nanlong
    Chen, Shiting
    Zheng, Zhiwei
    Song, Xiaobing
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 205 - 213
  • [6] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [7] Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma
    Gong, Jinhong
    Shang, Jingjing
    Su, Dan
    Qian, Xiaodan
    Liu, Guangjun
    Sun, Zhiqiang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2023, 23 (06) : 709 - 717
  • [8] Cost-effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma
    Zhang, Li
    Su, Henghai
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Yan
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [9] Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma
    Liu, Lulu
    Wang, Lei
    Chen, Li
    Ding, Yiling
    Zhang, Qilin
    Shu, Yamin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [10] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
12345